As Founder and Managing Partner of Newpath Partners, Dr. Thomas Cahill combines scientific rigor with entrepreneurial expertise to develop transformative therapies. He focuses on translating breakthroughs into treatments by partnering with leading academic scientists to incubate and scale early-stage opportunities. Newpath serves as a founding and lead investor, aligning the interests of investors, management, and employees from the outset.

Dr. Cahill is a director for several portfolio companies, including Prime Medicine, CREATE Medicines, Convergence Bio, Magnet Biomedicine, nChroma Bio, Autobahn Therapeutics, and Radian Bio. He is also active in domestic and international nonprofit and civic efforts.

He earned his MD and PhD from Duke University School of Medicine, where his research under Nobel laureate Robert Lefkowitz focused on cellular receptor biophysics. His work has received numerous awards and been published in peer-reviewed journals, and he remains engaged in basic science research within Newpath’s academic network.